Skip to the page

Data / Drug companies / Tablet, for suspension

Companies that list tablet, for suspension products: 36 companies and 84 products in the FDA NDC directory

The FDA National Drug Code Directory lists 84 products that are tablet, for suspension products from 36 companies. The ten largest listers hold 47.6% of them, and the newest started marketing on October 26, 2026.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Companies
36
Products
84
Drugs by generic name
15
Main marketing category
Generic drugs (ANDA)

Companies that list tablet, for suspension products

Ranked by number of products in commercial distribution.

CompanyProductsMain dosage formsMain marketing categoryNewest product started
Novartis Pharmaceuticals Corporation7tablet, for suspensionNew drug applications (NDA)March 16, 2023
Alembic Pharmaceuticals Inc.5tablet, for suspensionGeneric drugs (ANDA)November 21, 2019
Alembic Pharmaceuticals Limited5tablet, for suspensionGeneric drugs (ANDA)November 21, 2019
Aprecia Pharmaceuticals, LLC4tablet, for suspensionNew drug applications (NDA)February 5, 2016
Novartis Pharma Stein AG4tablet, for suspensionDrugs for further processingMarch 16, 2023
Amneal Pharmaceuticals NY LLC3tablet, for suspensionGeneric drugs (ANDA)January 14, 2025
Ani Pharmaceuticals, Inc.3tablet, for suspensionGeneric drugs (ANDA)October 10, 2025
Ascend Laboratories, LLC3tablet, for suspensionGeneric drugs (ANDA)November 22, 2019
Biocon Pharma Inc.3tablet, for suspensionGeneric drugs (ANDA)January 14, 2026
Bionpharma Inc.3tablet, for suspensionGeneric drugs (ANDA)September 28, 2018
Breckenridge Pharmaceutical, Inc.3tablet, for suspensionGeneric drugs (ANDA)January 28, 2025
Dr. Reddy's Laboratories Inc.3tablet, for suspensionGeneric drugs (ANDA)November 20, 2019
GlaxoSmithKline LLC3tablet, for suspensionNew drug applications (NDA)October 12, 2000
Glenmark Pharmaceuticals Inc., USA3tablet, for suspensionGeneric drugs (ANDA)January 6, 2020
MSN Laboratories Private Limited3tablet, for suspensionGeneric drugs (ANDA)November 20, 2019
Novadoz Pharmaceuticals LLC3tablet, for suspensionGeneric drugs (ANDA)November 20, 2019
Sun Pharmaceutical Industries, Inc.3tablet, for suspensionGeneric drugs (ANDA)December 2, 2019
Teva Pharmaceuticals, Inc.3tablet, for suspensionGeneric drugs (ANDA)November 1, 2024
Janssen Products, LP2tablet, for suspensionNew drug applications (NDA)February 27, 2026
Prasco Laboratories2tablet, for suspensionAuthorized generics (NDA)January 20, 2025
Actelion Pharmaceuticals US, Inc.1tablet, for suspensionNew drug applications (NDA)July 29, 2021
Burel Pharmaceuticals, LLC1tablet, for suspensionGeneric drugs (ANDA)December 19, 2022
E.r. Squibb & Sons, L.L.C.1tablet, for suspensionNew drug applications (NDA)September 15, 2025
Eton Pharmaceuticals, Inc.1tablet, for suspensionGeneric drugs (ANDA)December 20, 2021
Glaxo Operations Uk Ltd1tablet, for suspensionDrugs for further processingJune 12, 2020
Global Blood Therapeutics, Inc, a Subsidiary of Pfizer Inc.1tablet, for suspensionNew drug applications (NDA)December 17, 2021
Lupin Pharmaceuticals, Inc.1tablet, for suspensionGeneric drugs (ANDA)August 18, 2025
Navinta LLC1tablet, for suspensionGeneric drugs (ANDA)August 1, 2022
Patheon Inc.1tablet, for suspensionDrugs for further processingDecember 17, 2021
Pfizer Ireland Pharmaceuticals Unlimited Company1tablet, for suspensionDrugs for further processingJanuary 22, 2025
Rare Thyroid Therapeutics International AB1tablet, for suspensionNew drug applications (NDA)October 26, 2026
Recordati Rare Diseases1tablet, for suspensionNew drug applications (NDA)March 18, 2010
SpringWorks Therapeutics, Inc.1tablet, for suspensionNew drug applications (NDA)February 11, 2025
ViiV Healthcare Company1tablet, for suspensionNew drug applications (NDA)June 12, 2020
Zydus Lifesciences Limited1tablet, for suspensionGeneric drugs (ANDA)February 17, 2026
Zydus Pharmaceuticals USA Inc.1tablet, for suspensionGeneric drugs (ANDA)February 17, 2026

Drugs most often listed

DrugProducts hereCompanies listing it
Levetiracetam687
Lamotrigine551
Deferasirox3321
Everolimus1515
Apixaban18
Bosentan47
Carglumic acid44
Darunavir ethanolate and cobicistat12
Dolutegravir sodium12
Lamotrigine chewable dispersible21
Dabrafenib11
Mirdametinib11
Rilpivirine hydrochloride11
Tiratricol11
Voxelotor11

Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.